Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.38 |
| ▸ | STS | P08842 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 3/20 | 0.36 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27145110 | 1.00 | GPR119 (0.39) | GPR119TGFBR1NR1H2NR1H3STS | |
| SCHEMBL25254840 | 0.90 | GPR119 (0.40) | GPR119TGFBR1NR1H2NR1H3STS | |
| SCHEMBL29497018 | 0.90 | GPR119 (0.40) | GPR119TGFBR1NR1H2NR1H3STS | |
| SCHEMBL29497089 | 0.87 | GPR119 (0.50) | GPR119NR1H2NR1H3 | |
| SCHEMBL25258558 | 0.87 | GPR119 (0.50) | GPR119NR1H2NR1H3 | |
| SCHEMBL31532417 | 0.85 | ENPP2 (0.36) | GPR119RORC | |
| SCHEMBL30408969 | 0.84 | GPR119 (0.46) | GPR119RORC | |
| SCHEMBL31308789 | 0.83 | GPR119 (0.42) | GPR119TGFBR1NR1H2NR1H3STS | |
| SCHEMBL31308665 | 0.83 | GPR119 (0.42) | GPR119TGFBR1NR1H2NR1H3STS | |
| SCHEMBL30700768 | 0.83 | GPR119 (0.42) | GPR119TGFBR1NR1H2NR1H3STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068347-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2025-04-03 | — | — | WO | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| EP-4416154-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-08-21 | — | — | EP | disclosed |
| EP-4326714-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| WO-2023247670-A1 | NEW HETEROCYCLIC-CARBONYL-CYCLIC COMPOUNDS AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023062049-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-20 | — | — | WO | disclosed |
| WO-2022223750-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | GPR119 1935/4885TGFBR1 1999/4885NR1H2 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.